Product Description
Mechanisms of Action: TNF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: India
Approved Indications: None
Known Adverse Events: None
Company: Third Military Medical University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ChiCTR2500097292 | N/A |
Not yet recruiting |
Oncology Unspecified |
2025-08-31 |
|||
| ChiCTR2000034019 | N/A |
Recruiting |
Prostate Cancer |
2024-06-23 |
|||
| KLKN 14-04-2014 | N/A |
Completed |
Bone Diseases, Metabolic|Osteoporosis |
2016-10-01 |
2025-02-07 |
Primary Endpoints|Treatments |
|
| 4P-07-3 | P2 |
Completed |
Prostate Cancer |
2014-07-08 |
2025-02-07 |
Primary Endpoints|Treatments |
|
| ISOII | N/A |
Completed |
Menopause |
2012-09-01 |
2019-03-19 |
Treatments |
|
| CUHKGRF465810 | N/A |
Unknown status |
Hypertension |
2012-06-01 |
2019-03-19 |
Treatments |
|
| ChiCTR-TRC-11001222 | N/A |
Completed |
Osteoporosis, Postmenopausal |
2011-12-31 |
|||
| ChiCTR-TRC-10001048 | N/A |
Completed |
Unknown |
2011-12-30 |
|||
| yanbinye | N/A |
Completed |
Type 2 Diabetes |
2011-06-01 |
2019-03-18 |
Treatments |
|
| SoyPTI | N/A |
Completed |
Osteoporosis |
2004-01-01 |
2019-03-18 |
Treatments |